CLDI — Calidi Biotherapeutics Balance Sheet
0.000.00%
- $16.67m
- $11.50m
Annual balance sheet for Calidi Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 0.42 | 2.14 | 0.372 | 1.95 | 9.59 |
Net Total Receivables | — | — | — | — | 0 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 0.513 | 2.74 | 0.786 | 4.3 | 10.2 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.723 | 0.585 | 1.09 | 5.34 | 3.8 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 1.85 | 3.39 | 2.6 | 10 | 14.2 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 8.89 | 26 | 43 | 10.2 | 9.5 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 15.3 | 26 | 43.4 | 18.3 | 12.6 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -13.5 | -22.6 | -40.8 | -8.23 | 1.53 |
Total Liabilities & Shareholders' Equity | 1.85 | 3.39 | 2.6 | 10 | 14.2 |
Total Common Shares Outstanding |